Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin.
In an open multicentre drug monitoring survey, 1611 patients with atopic dermatitis, contact eczema, dry eczema, psoriasis and pruritus were treated with a preparation containing 5% urea and 3% polidocanol (laurylmacrogol). To monitor the course of treatment, three examinations were performed, one at the start of therapy and two more at intervals of approximately two weeks. A marked improvement in the status of the skin was observed during treatment. A marked regression occurred in the principal signs of dry skin--scaling, dryness and roughness. Troublesome itching was also greatly reduced. Almost half of the patients (48.9%) were free of itching at the end of the observation period. Adverse drug effects arose in only 2.8% of cases, and were mostly smarting, itching and irritation. No intolerance reactions were observed in children under six years. At the end of the observation period the skin status was judged, by both the doctors and the patients as 'good' or 'very good' in almost 90% of cases. Furthermore, the assessment with regard to the regression of itching was almost identical.
Freitag
G
G
Medical Science Department, HERMAL, Reinbek, Germany.
Höppner
T
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004338:Drug Combinations; D004485:Eczema / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D000077423:Polidocanol; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011358:Product Surveillance, Postmarketing; D011537:Pruritus / Q000188:drug therapy*; D011565:Psoriasis / Q000188:drug therapy*; D014508:Urea / Q000008:administration & dosage*
D004338:Drug Combinations; D000077423:Polidocanol; D011092:Polyethylene Glycols; D014508:Urea